What Do Laurus Labs, Hindustan Unilever, and Jindal Saw Reveal in Their Latest Concall Updates?
Indian corporates continued to share forward-looking insights in their recent earnings concalls, offering clarity on growth, capital expenditure, and margin outlook for FY26. Laurus Labs guided for strong ARV segment performance and steady gross margins, Hindustan Unilever (HUL) expects margin recovery post its ice cream business demerger, and Jindal Saw sees gradual operational improvement from Q3 FY26. These updates reflect diverse industry momentum across pharma, FMCG, and industrial manufacturing sectors.
Laurus Labs – CDMO Expansion and ARV Stability
Laurus Labs has guided for ARV (antiretroviral) sales of approximately ₹2,500 crore, ±₹200 crore, driven by higher procurement from global health agencies. The company plans a substantial capital expenditure of ₹1,000 crore for FY26, focusing on small and large molecule CDMO (Contract Development and Manufacturing Organization) capabilities. It also announced a long-term plan to invest around USD 600 million over eight years for a new 530-acre complex, separate from existing facilities.
Track pharma momentum and market data shifts with our expert Nifty Option Tip for data-driven strategies in the healthcare sector.
| Metric | FY26 Guidance | Commentary |
|---|---|---|
| ARV Sales | ₹2,500 Cr ± ₹200 Cr | Stable demand; recovery in tender business |
| Capex FY26 | ₹1,000 Cr | Capacity expansion; CDMO growth |
| Gross Margin | ~60% | Improved vs earlier 50–55% guidance |
| Asset Turnover | Target 1.1x | From current 0.9x, with better utilisation |
Laurus Labs expects improved EBITDA margins as its product mix tilts toward high-value CDMO contracts and oncology APIs. The management emphasized that its newer facilities are designed for scalable global demand, enhancing return on capital employed (ROCE) over the medium term.
Hindustan Unilever – Margin Guidance and Ice Cream Demerger
Hindustan Unilever provided a cautiously optimistic outlook, expecting stronger growth in H2 FY26 versus H1. The company guided near- to mid-term EBITDA margins of 22–23% and anticipates an additional 50–60 basis points improvement post the ice cream business demerger. The demerger is targeted for completion by December 2025, with the new listing anticipated in Q4 FY26, subject to regulatory approvals.
Management attributed the temporary softness in H1 to GST-related price normalization, expecting normal trade patterns from November onward. The company’s low single-digit price growth guidance assumes stable commodity prices.
For tactical ideas in FMCG and consumer stocks, explore our weekly BankNifty Intraday Tip crafted for sectoral momentum traders.
| Metric | Guidance / Timeline | Details |
|---|---|---|
| EBITDA Margin | 22–23% | Target range for near- to mid-term |
| Margin uplift post demerger | +50–60 bps | Ice cream business separation benefit |
| Ice Cream Listing | Q4 FY26 | Subject to approvals |
Analysts interpret HUL’s guidance as a signal of near-term margin bottoming. As price increases stabilize and volume growth recovers, profitability could trend back toward the upper end of management’s guidance band by FY26-end.
Jindal Saw – Gradual Recovery Path
Jindal Saw expects operations and financial performance to gradually improve from Q3 FY26 onwards. The management highlighted that some Middle East projects would only partially commence operations by FY29, implying limited contribution in FY28. The company continues to focus on cost control and pipeline product diversification.
Investors should note that delayed overseas project monetization could temper near-term returns, but improved domestic order flow and debt reduction efforts remain positives for the medium term.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, notes that Laurus Labs’ consistent execution in CDMO and ARV segments offers structural growth visibility, while Hindustan Unilever’s improving margin trajectory reinforces its defensive strength. Jindal Saw’s long project cycle requires patience but retains strategic relevance in infrastructure. Collectively, these updates highlight India’s cross-sector resilience and the importance of selective positioning based on visibility and execution strength.
Discover more analytical insights and sectoral commentary at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Related Queries on Company Concall Highlights
- How is Laurus Labs’ CDMO strategy shaping future growth?
- When will HUL’s ice cream business list separately?
- Why is Jindal Saw projecting limited contribution from Middle East projects before FY29?
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
